20 results
8-K
EX-99.1
MLYS
Mineralys Therapeutics, Inc.
13 Aug 24
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
4:07pm
planned clinical studies, as well as support corporate operations, into 2026.
Research and Development (R&D) expenses for the quarter ended June 30, 2024 … research and development expenses.
General and Administrative (G&A) expenses were $5.9 million for the quarter ended June 30, 2024, compared to $3.9
8-K
EX-99.1
MLYS
Mineralys Therapeutics, Inc.
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
in other research and development expenses, partially offset by a decrease of $4.0 million in license fees.
General and Administrative (G&A) expenses … Months Ended
March 31,
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest
424B5
MLYS
Mineralys Therapeutics, Inc.
11 Apr 24
Prospectus supplement for primary offering
4:35pm
candidate, research and development, manufacturing, general and administrative expenses, license or technology acquisitions, and working capital and capital … candidate, research and development, manufacturing, general and administrative expenses, license or technology acquisitions, and working capital
8-K
EX-99.1
kjy7fqkh
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
S-3
EX-1.2
8627zz9 4q2gfgw
21 Mar 24
Shelf registration
7:30am
S-3
tzyzq
21 Mar 24
Shelf registration
7:30am
8-K
EX-99.1
d8c ntkqkg6
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
kgpcm976y lk
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-99.1
a9myi1h0skh1jydf4
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
vfncjwjjak0jz abrhyq
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
10-Q
9xr2pgl2l3x3 p9fgcvg
15 May 23
Quarterly report
5:25pm
8-K
EX-99.1
fijn7lab889xepo8q
15 May 23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
DRS/A
zudjkfcugc9
29 Dec 22
Draft registration statement (amended)
12:00am
DRS/A
biulzs4zlwdz5btz4u
7 Dec 22
Draft registration statement (amended)
12:00am
DRS
llx8xzq 0iha4
4 Nov 22
Draft registration statement
12:00am
- Prev
- 1
- Next